Logo image of ARTV

ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Fundamental Analysis

USA - NASDAQ:ARTV - US04317A1079 - Common Stock

3.25 USD
-0.14 (-4.13%)
Last: 11/14/2025, 8:00:00 PM
3.31 USD
+0.06 (+1.85%)
After Hours: 11/14/2025, 8:00:00 PM
Fundamental Rating

3

ARTV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. While ARTV has a great health rating, there are worries on its profitability. ARTV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ARTV had negative earnings in the past year.
ARTV had a negative operating cash flow in the past year.
ARTV Yearly Net Income VS EBIT VS OCF VS FCFARTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -44.08%, ARTV perfoms like the industry average, outperforming 55.91% of the companies in the same industry.
Looking at the Return On Equity, with a value of -50.09%, ARTV is in the better half of the industry, outperforming 65.48% of the companies in the same industry.
Industry RankSector Rank
ROA -44.08%
ROE -50.09%
ROIC N/A
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARTV Yearly ROA, ROE, ROICARTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARTV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARTV Yearly Profit, Operating, Gross MarginsARTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

ARTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARTV has more shares outstanding
The debt/assets ratio for ARTV is higher compared to a year ago.
ARTV Yearly Shares OutstandingARTV Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
ARTV Yearly Total Debt VS Total AssetsARTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -0.64, we must say that ARTV is in the distress zone and has some risk of bankruptcy.
ARTV has a Altman-Z score (-0.64) which is comparable to the rest of the industry.
ARTV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.64
ROIC/WACCN/A
WACC8.77%
ARTV Yearly LT Debt VS Equity VS FCFARTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ARTV has a Current Ratio of 13.84. This indicates that ARTV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 13.84, ARTV belongs to the best of the industry, outperforming 89.49% of the companies in the same industry.
ARTV has a Quick Ratio of 13.84. This indicates that ARTV is financially healthy and has no problem in meeting its short term obligations.
ARTV has a better Quick ratio (13.84) than 89.49% of its industry peers.
Industry RankSector Rank
Current Ratio 13.84
Quick Ratio 13.84
ARTV Yearly Current Assets VS Current LiabilitesARTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ARTV have decreased strongly by -370.69% in the last year.
ARTV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.25%.
ARTV shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -49.95% yearly.
EPS 1Y (TTM)-370.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.05%
Revenue 1Y (TTM)-99.25%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 7.50% on average over the next years.
ARTV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 212.71% yearly.
EPS Next Y34.13%
EPS Next 2Y16.54%
EPS Next 3Y14.53%
EPS Next 5Y7.5%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y212.71%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARTV Yearly Revenue VS EstimatesARTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ARTV Yearly EPS VS EstimatesARTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ARTV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARTV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARTV Price Earnings VS Forward Price EarningsARTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARTV Per share dataARTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

ARTV's earnings are expected to grow with 14.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.54%
EPS Next 3Y14.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARTV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARTIVA BIOTHERAPEUTICS INC

NASDAQ:ARTV (11/14/2025, 8:00:00 PM)

After market: 3.31 +0.06 (+1.85%)

3.25

-0.14 (-4.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-18 2025-11-18
Inst Owners71.23%
Inst Owner Change-1.5%
Ins Owners0.82%
Ins Owner Change-1.17%
Market Cap79.40M
Revenue(TTM)N/A
Net Income(TTM)-74.66M
Analysts85
Price Target16.73 (414.77%)
Short Float %1.11%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.13%
Min EPS beat(2)-14.53%
Max EPS beat(2)-5.74%
EPS beat(4)2
Avg EPS beat(4)-1.31%
Min EPS beat(4)-14.53%
Max EPS beat(4)14.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.49%
PT rev (3m)6.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-3.28
EYN/A
EPS(NY)-3.48
Fwd EYN/A
FCF(TTM)-2.89
FCFYN/A
OCF(TTM)-2.82
OCFYN/A
SpS0
BVpS6.1
TBVpS6.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.08%
ROE -50.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.84
Quick Ratio 13.84
Altman-Z -0.64
F-Score3
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)238.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)131.08%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-370.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.05%
EPS Next Y34.13%
EPS Next 2Y16.54%
EPS Next 3Y14.53%
EPS Next 5Y7.5%
Revenue 1Y (TTM)-99.25%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y212.71%
EBIT growth 1Y-119.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.03%
OCF growth 3YN/A
OCF growth 5YN/A

ARTIVA BIOTHERAPEUTICS INC / ARTV FAQ

What is the ChartMill fundamental rating of ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ARTV.


What is the valuation status of ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

ChartMill assigns a valuation rating of 0 / 10 to ARTIVA BIOTHERAPEUTICS INC (ARTV). This can be considered as Overvalued.


How profitable is ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

ARTIVA BIOTHERAPEUTICS INC (ARTV) has a profitability rating of 1 / 10.


What is the expected EPS growth for ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

The Earnings per Share (EPS) of ARTIVA BIOTHERAPEUTICS INC (ARTV) is expected to grow by 34.13% in the next year.